Bio

Adam Freiman is a leading corporate lawyer who possesses a deep understanding of the emerging company ecosystem and the technology and life sciences markets. His knowledge and ability to serve the vast needs of today's most innovative technology and life sciences companies is backed by his 25 years of experience in handling the complex business transactions and legal issues they face. Mr. Freiman offers solutions-focused, strategic advice and an indispensable business perspective that is critical to clients’ success. Mr. Freiman works closely with a wide range of companies at all stages of their life cycle, from incorporation to exit. He advises high-growth companies on a diverse range of critical transactions, including early and late-stage financings as well as exit transactions, including IPOs and sale transactions. He has extensive experience advising on both buy-side and sell-side M&A transactions. He also advises clients on complex corporate governance matters, joint ventures and strategic transactions. In addition, Mr. Freiman regularly represents venture capital and growth equity funds, private equity funds and other investors in making and managing their investments and in exit transactions. Mr. Freiman also has experience representing both issuers and underwriters in connection with IPOs and other public offerings, private placement transactions, and exchange and tender offers, as well as advising public company clients on SEC reporting and disclosure requirements.